Shares of ProNAi Therapeutics Inc. (NASDAQ:DNAI) were down 0.5% during trading on Friday . The company traded as low as $2.01 and last traded at $2.06, with a volume of 362,203 shares traded. The stock had previously closed at $2.05.

A number of analysts have commented on DNAI shares. Zacks Investment Research lowered shares of ProNAi Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, May 4th. Wedbush reaffirmed an “outperform” rating and set a $36.00 target price on shares of ProNAi Therapeutics in a report on Friday, May 27th. Jefferies Group reaffirmed a “buy” rating on shares of ProNAi Therapeutics in a report on Sunday, May 29th. Finally, SunTrust Banks Inc. lowered shares of ProNAi Therapeutics from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $25.00 to $4.00 in a report on Monday, June 6th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $17.35.

The stock’s market capitalization is $62.16 million. The stock’s 50-day moving average is $3.23 and its 200 day moving average is $6.60.

ProNAi Therapeutics (NASDAQ:DNAI) last issued its quarterly earnings results on Tuesday, May 10th. The company reported ($0.35) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.07. On average, equities research analysts expect that ProNAi Therapeutics Inc. will post ($1.33) earnings per share for the current fiscal year.

An institutional investor recently raised its position in ProNAi Therapeutics stock. Greenleaf Trust increased its stake in shares of ProNAi Therapeutics Inc. (NASDAQ:DNAI) by 96.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 190,812 shares of the company’s stock after buying an additional 93,812 shares during the period. Greenleaf Trust owned approximately 0.63% of ProNAi Therapeutics worth $2,870,000 as of its most recent filing with the SEC.

ProNAi Therapeutics, Inc is a clinical-stage oncology company. The Company is engaged in business of researching, developing and commercializing therapies for the treatment of patients with cancer and hematological diseases based on its deoxyribonucleic acid interference (DNAi) technology platform. Its lead product candidate includes PNT2258, which targets cancers that overexpress B-cell lymphoma 2 (BCL2), an oncogene known to be dysregulated in various types of cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.